Table 1.
Patients enrolled in the Long Antagonist Protocol proof of concept study.
| Age | AMH (ng/ml) | Luteal day antagonist | Menses | FSH day initiation | Stimulation days | Triggering | COCs | MII | 2PN | Total embryos | Pregnancy outcome | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A study OD | OD patients | |||||||||||
| ID-01 | 28 | 2.5 | d-24 | d-27 | CycDay10 | 11 | GnRH | 10 | 8 | 6 | 2 D5 | Heterotopic |
| ID-02 | 24 | 4.59 | d-26 | d-28 | CycDay08 | 10 | GnRH | 29 | 22 | 16 | 10 D5 | Ongoing |
| ID-03 | 28 | 2.1 | d-24 | d-27 | CycDay06 | 10 | GnRH | 15 | 15 | 14 | 6 D5 | Ongoing |
| ID-04 | 31 | 2.8 | d-24 | d-26 | CycDay09 | 11 | GnRH | 17 | 10 | 10 | 4 D5 | Negative |
| ID-05 | 26 | 2.0 | d-24 | d-26 | CycDay07 | 11 | GnRH | 13 | 11 | 10 | 2 D5 | Ongoing |
| B study IVF | IVF patients | |||||||||||
| ID-06 | 30 | 3.49 | d-24 | d-26 | CycDay08 | 10 | rec-HCG | 16 | 12 | 11 | 6 D5 | Delivery |
| ID-07 | 34 | 3.0 | d-24 | d-28 | CycDay06 | 10 | rec-HCG | 16 | 13 | 9 | 4 D5 | Clinical |
| ID-08 | 39 | 2.4 | d-24 | d-27 | CycDay04 | 11 | rec-HCG | 6 | 6 | 6 | 3 D5 | Negative |
| ID-09 | 27 | 4.48 | d-26 | d-28 | CycDay03 | 11 | GnRH | 22 | 19 | 19 | 16 D5 | Frall/Clinical |
| ID-10 | 33 | 1.47 | d-24 | d-26 | CycDay02 | 11 | rec-HCG | 7 | 5 | 3 | 2 D5 | Clinical |
FSH, follicle-stimulating hormone; GnRH, gonadotropin-releasing hormone; HCG, human chorionic gonadotropin; IVF, in vitro fertilization.